Ariad Pharmaceuticals, Inc. Shares Dive as Drug Sale Halted

Published: Nov 01, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Ariad Pharmaceuticals’ stock plunged yesterday on news that the Cambridge company was suspending sales of its leukemia drug Iclusig because of concerns that patients taking it could suffer life-threatening blood clots. Shares dropped more than 44 percent to $2.20 on the Nasdaq stock exchange after federal regulators asked it to stop marketing the drug. Ariad first disclosed a higher rate of side effects related to blood clots Oct. 9. - See more at:

Help employers find you! Check out all the jobs and post your resume.

Back to news